Biologics in Respiratory Medicine

BTS is pleased to offer this series of three webinar recordings to share learning on the use of biologic treatment for patients with Eosinophilic granulomatosis with polyangiitis (EGPA), asthma and COPD.

Anti-IL5R and other treatment approaches in the management of EGPA

Recorded: 7 October 2025
Speakers: Prof David Jackson (London) & Dr Rona Smith (Cambridge)

Benralizumab has recently become the first NICE-approved biologic treatment for Eosinophilic granulomatosis with polyangiitis (EGPA). This rare heterogeneous condition is defined by the presence of eosinophilic inflammation leading to clinical remission rates of approximately 60% with benralizumab. However, other inflammatory pathways are frequently involved requiring a personalised multidisciplinary approach to management.

In this webinar the speakers reviewed clinical trial data, the new NICE guidance and discussed how to approach and manage patients with EGPA. 

Navigating the complexity of asthma biologics: from choice to delivery

Recorded: 22 October 2025
Speakers: Dr Alexandra Nanzer-Kelly (London) & Helena Cummings (Hull)

The right treatment for the right patient with severe asthma can be transformative but requires an in-depth knowledge of responder characteristics, causes of persisting symptoms whilst on biologic treatment and common reasons for treatment failure. Equally important is a clear understanding of how to deliver ongoing care in patients established on biologics. This webinar covered the key aspects relating to the holistic management of patients with severe asthma covering both medical and nursing aspects of biologic delivery.

COPD Biologics Webinar

Recorded: 2 December 2025
Chair: Dr Lydia Finney
Speakers: Professor Mona Bafadhel and Dr Neil Greening

Hear the latest updates on biologic treatments for COPD.

The session covered updates on 2 the large trials - Professor Bafadhel provided an update on the BenRAlizumab (ABRA) trial and Dr Greening talked about the COPD-HELP study.